We are live on ! Find out more

Nyxoah

NYXH

Market cap $90.4M

0.8879 USD

-0.0121

1.34%

At close Updated Oct 29, 4:00 PM EDT

1 day

-1.34%

5 days

2.92%

1 month

-35.19%

3 months

-36.12%

6 months

-69.7%

Year to date

-80.27%

1 year

-82.59%

5 years

-96.46%

10 years

-97.05%

About: Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Employees: 154

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.2%

Neutral 81.8%

Negative 0%

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026 Mont-Saint-Guibert, Belgium – October 26, 2026, 10:05 pm CET / 5:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the third quarter of 2026 on Thursday, November 5, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30 pm CET / 4:30 pm ET.

Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026

Zacks Investment Research

Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher

Nyxoah (NYXH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Nyxoah (NYXH) Could be Great Choice for a Bottom Fisher

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026 U.S. net revenue grows 29% sequentially, driving third quarter global preliminary net revenue of €9.2 million PMA supplement submitted to the FDA to expand Genio's U.S. indication to Complete Concentric Collapse patients Mont-Saint-Guibert, Belgium – October 19, 2026, 2:00 pm CET / 08:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited third quarter 2026 financial and operating results and adjusted revenue guidance for 2026. Third Quarter 2026 – Preliminary Sales and Market Metrics Financials Global net revenue is expected to be approximately €9.2 million in the third quarter of 2026, which reflects 19% sequential growth over the second quarter of 2026 U.S. net revenue is expected to be approximately €6.7 million in the third quarter of 2026, which reflects 29% sequential growth over the second quarter of 2026 Leading U.S. commercial indicators 80 new surgeons trained in Q3, bringing the total to 342 surgeons trained 53 new accounts activated in Q3, bringing the total to 233 active high-volume accounts 447 patients actively under prior authorization entering Q4 Clinical and Regulatory ACCCESS U.S. pivotal study met its co-primary efficacy endpoints and its safety endpoints in Complete Concentric Collapse (CCC) patients, with a 12-month AHI responder rate of 77.2% (p

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.

Nyxoah is entering its first growth stage, targeting the OSA device market with the Genio implant, and is currently undervalued relative to growth prospects. Genio could secure a monopoly on 30% of the OSA market by 2027, pending FDA label extension for Complete Concentric Collapse (CCC) patients, supported by strong clinical trial results. NYXH projects €36 million revenue for 2026, up 260% YoY, with visibility supported by rapid growth in trained surgeons, active accounts, and prior authorizations.

Nyxoah: Label Expansion Set To Unlock A Monopoly In A Billion Dollar Market.

Nyxoah Appoints Liam Kelly as Chief Executive Officer

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Appoints Liam Kelly as Chief Executive Officer Further strengthening the Company's strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. The appointment reflects Nyxoah's continued evolution into a U.S.-focused commercial organization following FDA approval and the launch of Genio in the United States.

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Nyxoah Announces Chief Financial Officer Transition

REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Chief Financial Officer Transition Loïc Moreau, Nyxoah's President International and former CFO, to serve as interim CFO Company reaffirms full year 2026 financial guidance Mont-Saint-Guibert, Belgium – September 21, 2026, 22:01h CET / 4:01h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role effective October 2, 2026 to pursue another professional opportunity. Loïc Moreau, the Company's President International and former CFO, will serve as Interim CFO effective upon Mr.

Nyxoah Announces Chief Financial Officer Transition

Zacks Investment Research

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.

Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System

Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Nyxoah Q2 Earnings Call Highlights

Nyxoah NASDAQ: NYXH reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequentially to €2.5 million.

Nyxoah Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™